The Antibiotic That Didn’t Work — Kerbside Consult 23/2026

A patient has fever and cough. He expects an antibiotic because it helped last time. The consultation is already running late. Explaining why an antibiotic is unnecessary will take longer than printing a prescription.

Elsewhere, someone asks a pharmacist for “the same capsule” without a prescription. Another patient saves unfinished treatment for the next illness. Each decision feels small. Antimicrobial resistance is what happens when millions of small decisions meet bacterial evolution.

Resistance is already here

Antimicrobial resistance, or AMR, occurs when microorganisms change so that medicines that once treated them no longer work reliably. The human body is not becoming resistant. The organism is.

“Why not give me a stronger antibiotic?” Because the supply of useful alternatives is not endless. A broader or newer drug may be more toxic, more expensive, injectable rather than oral, and will itself come under pressure from resistance.

A major analysis estimated that bacterial AMR directly caused 1.14 million deaths in 2021 and could cause 1.91 million deaths annually by 2050. In 2025, the World Health Organization reported that about one in six laboratory-confirmed bacterial infections causing common infections in 2023 was resistant to antibiotic treatment.

Resistance is not a future pandemic waiting to begin. It is already a clinical and public-health problem — seen every day in hospitals, clinics and communities.

Global numbers do not tell a Malaysian doctor what is likely to work in the patient sitting opposite. That requires an accurate diagnosis, local resistance data and, when appropriate, a specimen taken before treatment.

Malaysia has a framework. Does it reach the front line?

Malaysia is not starting from zero. We have the Malaysian Action Plan on Antimicrobial Resistance 2022–2026, national surveillance, an updated National Antimicrobial Guideline and a formal stewardship protocol.

The hospital burden is substantial. Surveillance covering 148 MOH hospitals and three university hospitals recorded 26,806 multidrug-resistant organism isolates in 2024, up from 19,757 in 2023. But this dataset excludes Emergency Departments, clinics and other outpatient services. It tells us much about hospitals, but not enough about resistance or prescribing in primary care.

The MOH stewardship protocol does reach beyond hospitals. It calls for AMS teams in eligible public health clinics, surveillance of antibiotic use, regular clinical audit and feedback to prescribers. This is a real primary-care framework.

What is less visible is how consistently it is implemented, what the audits show and what changes after feedback. The public data are even thinner for private GP practices and community pharmacies, where many everyday antibiotic decisions are made. That is an information gap, not proof that nothing is being done.

MMA has called for rational prescribing, better access to community resistance data and continuing public education. It also joined MOH and other partners in a 2025 primary-care stewardship programme. I could not, however, identify one current MMA document bringing together measurable prescribing and audit expectations for private general practice.

Antibiotics are also not ordinary retail products. Under Malaysia’s Poisons Act and current Poisons List, pharmaceutical antibiotic preparations placed in Group B generally require a prescription. The narrow urgent-supply procedure is not a general over-the-counter exception.

Malaysia does not lack policies. The weakness is the last mile: what happens when a patient asks a GP or pharmacist for an antibiotic — and whether those decisions are measured.

A useful audit need not be punitive. It can ask a few practical questions: Was an antibiotic indicated? Was the first-line drug used? Were dose and duration documented? Was safety-net advice given? For pharmacies: was a valid prescription present, and was the patient advised not to share or reuse leftovers?

Numbers must still be interpreted fairly. A clinic caring for frail or immunocompromised patients should not be compared crudely with a low-risk practice. Audit should guide better care, not reward the lowest prescribing rate at any cost.

How — and when — to say no

“No antibiotic” must never sound like “no treatment” or “your illness is not real”.

A useful consultation has five steps:

Name the likely diagnosis. “This looks most consistent with a viral upper-respiratory infection.”
Explain why an antibiotic will not help. Antibiotics treat bacteria, not viruses; an unnecessary drug adds risk without shortening the illness.
Offer active treatment. Discuss fluids, rest, analgesia, fever control or other symptom relief appropriate to the patient.
Give a time course. Tell the patient what usually improves first and how long symptoms may reasonably last.
Safety-net clearly. Specify which symptoms require review, urgent care or emergency assessment.

A possible GP script

“You are unwell, but today I do not see evidence that an antibiotic will help. Taking one would expose you to side effects and makes resistant infection more likely in the future. Let us treat the symptoms, and I want you reviewed if you develop difficulty breathing, persistent high fever, confusion, dehydration, worsening pain, or if you are not improving as expected.”

Sometimes uncertainty is real. Where clinically appropriate, delayed prescribing or a planned review can create time for the illness to declare itself. But delayed prescribing is not a substitute for examining the patient, recognising risk or arranging follow-up.

A possible pharmacy script

“This antibiotic requires a prescription and may not be the right treatment for your symptoms. I can help with appropriate symptom relief, or refer you for medical assessment. If you have breathing difficulty, severe weakness, confusion, dehydration or rapidly worsening symptoms, please seek urgent care.”

There are times not to say no. Suspected sepsis, meningitis, severe bacterial infection and other time-critical presentations require prompt assessment and appropriate empiric treatment. Stewardship must never delay a lifesaving antibiotic.

When an antibiotic is prescribed, the message is simple: take it exactly as directed. Do not skip doses, share it, save it, restart it independently, or change the duration without professional advice. “Always finish every course” is too blunt when a clinician may appropriately change or stop treatment after review.

Educating the public without blaming them

It is easy to tell patients not to demand antibiotics. But prescribers prescribe, suppliers supply, and busy systems can make a quick prescription easier than a careful explanation.

Say no to antibiotics when they will not help — not no to examination, explanation or treatment.

Patients should be encouraged to ask:

What diagnosis are we treating?
Is this likely bacterial?
What benefit should I expect from the antibiotic?
What should I do if I become worse?

The message must appear where decisions are made: clinics, pharmacy counters, schools, discharge counselling and social media, in Malaysia’s major languages. Success is not the number of posters printed. It is fewer unnecessary requests, prescriptions and supplies — without delaying treatment for serious infection.

What should happen next?

Malaysia does not need to invent stewardship again. It needs to make the existing system visible at the point of care.

Publish usable local data so clinicians can see what is happening in their own setting.
Extend audit and feedback across public and private primary care.
Make pharmacy compliance visible and support pharmacists who refuse non-prescription requests.
Give the professions one clear message with practical tools for the consultation room and pharmacy counter.
Measure behaviour, not publicity. Awareness matters only if prescribing, supply and use improve.

Every antibiotic prescription is a decision about today’s patient and tomorrow’s treatment. The aim is not to use fewer antibiotics at any cost. It is to use them well, while they still work.

The laboratory report may say “resistant”. What it is really telling us is that choices made before this patient arrived now matter.

The next choice is ours.

Sources & further reading

Malaysia: policy, guidance and surveillance

Malaysian professional and clinical perspectives

Global evidence

Published 23/2026 · 19 September 2026 · No corrections to date · Corrections policy